Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
2012
No trial phase data available
No trial data available
No trial data available
No approval data available
- DaltonTx has officially launched Dalton, an AI-powered drug discovery platform that unifies data, models, and experimental results into a continuous learning engine for both small-molecule and biologic medicines. - Sygnature Discovery, a leading integrated drug discovery CRO, has signed on as the first client and is conducting a retrospective evaluation using a legacy oncology program currently in Phase I. - The platform differentiates itself through data privacy, siloing customer data and AI models on a per-program basis to ensure proprietary information is not used to train models for other projects. - DaltonTx was founded by former scientists from AstraZeneca, Exscientia, and the University of Oxford, positioning the company to compete in the increasingly crowded AI drug discovery market.
- The systematic integration of multiomics data with artificial intelligence is transforming drug R&D, enabling holistic systems biology interrogation and therapeutic target identification beyond traditional single-omics approaches. - AI-driven multiomics frameworks accelerate target discovery across oncology, neurology, and cardiovascular diseases, with CRISPR-based functional genomics and single-cell technologies revealing clinically actionable vulnerabilities such as EGFR, KRAS, and BCL2. - Generative AI models like GENTRL have demonstrated the ability to design potent small-molecule inhibitors in as little as 21 days, while AI-powered drug repurposing platforms have identified baricitinib and other candidates for Alzheimer's disease. - Key challenges persist including data harmonization across platforms, algorithmic interpretability of black-box models, and bridging the gap between in silico predictions and experimental validation in clinical settings.
- Paris-based Generare raised €20 million in Series A funding to expand its platform that decodes microbial genomes to discover previously inaccessible small molecules for drug discovery. - The company discovered more than 200 novel molecules in 2025 alone, outpacing all other players in the field combined who found only a few dozen new compounds. - Generare aims to scale its molecular library tenfold by 2027 to over 2,000 molecules, targeting the estimated 97% of genomic data buried in unexplored microbial genomes. - The funding will support expansion of the company's proprietary dataset and platform capabilities, positioning it to supply differentiated chemical starting points for next-generation AI drug discovery algorithms.
- Recursion received a $30 million milestone payment from Roche and Genentech for delivering a whole-genome phenotypic map of microglial cells, bringing total partnership payments to over $500 million. - The company's CDK7 inhibitor REC-617 established a maximum tolerated dose of 10 mg once-daily in Phase 1/2 trials, with manageable safety profile and preliminary anti-tumor activity in 29 heavily pre-treated patients. - REC-7735, a precision-designed PI3Kα H1047R inhibitor, was nominated as a development candidate and demonstrated significant tumor regressions at low doses while maintaining high selectivity over wild-type PI3Kα. - The company maintains a strong financial position with approximately $785 million in cash and cash equivalents, providing runway through the end of 2027 without additional financing.
- Recursion Pharmaceuticals announced that Najat Khan, Ph.D., will succeed co-founder Chris Gibson as CEO and President effective January 1, 2026, following unanimous Board approval. - Khan brings extensive experience from Johnson & Johnson where she helped triple pipeline value and built an industry-leading data science organization as Chief Data Science Officer. - Gibson will transition to Chairman of the Board while current Chairman Rob Hershberg becomes Vice-Chairman and Lead Independent Director. - The leadership change aims to drive Recursion's next phase of growth as the TechBio company advances its AI-powered drug discovery platform and clinical pipeline.
- DaltonTx, a UK-based technology company, has completed a £4 million seed financing round to develop adaptive AI-enabled discovery platforms that reshape R&D economics and timelines. - The company's disease- and technology-agnostic platform integrates directly into pharma, biotech, and CRO workflows, providing immediate access to AI-enabled discovery capabilities. - Founded by experts from AstraZeneca, Exscientia, and Oxford University, DaltonTx offers a reasoning engine that learns from every scientist, model, and experiment to continuously improve outcomes. - The platform supports both small molecules and biologics discovery, enabling collaborative intelligence between human expertise and machine learning systems.
- Sanofi has committed up to $25 million in strategic investment to Adagene, extending the biotech's cash runway into 2027 and supporting clinical development of its lead SAFEbody candidate muzastotug. - The partnership includes Sanofi exercising its option on a third SAFEbody discovery program and sponsoring a combination clinical trial with muzastotug in over 100 patients with advanced solid tumors. - Adagene's SAFEbody technology uses precision masking to enable tumor-specific targeting while minimizing toxicity in healthy tissues, addressing key safety challenges in cancer immunotherapy. - The collaboration reinforces Sanofi's aggressive R&D expansion strategy, following recent major deals including a $5.2 billion alliance with Exscientia and acquisitions totaling over $6 billion in immuno-oncology assets.
- Insilico Medicine closed an oversubscribed Series E financing round totaling $123 million, led by Value Partners Group, to advance its AI-driven drug discovery platform and clinical pipeline. - The company has built a pipeline of over 30 assets with 10 receiving IND clearance, including rentosertib for idiopathic pulmonary fibrosis currently in Phase 2a trials. - Insilico filed for its third Hong Kong IPO attempt in 2025, following previous filings in September 2024, amid growing investor interest in AI biotech companies. - The funding will support clinical validation of AI-driven drug programs and further development of the company's Pharma.AI platform and automated laboratory capabilities.
• Google has announced TxGemma, a collection of open AI models designed to streamline drug discovery by understanding both text and therapeutic entity structures, set for release through its Health AI Developer Foundations program. • Built on the Gemma model family, TxGemma comes in three sizes (2B, 9B, and 27B parameters) with specialized versions for classification, regression, and generation tasks, outperforming specialized models in 64 of 66 key benchmarks. • The initiative aims to address the high failure rate in drug development, where 90% of candidates don't progress past phase 1 trials, by enhancing prediction capabilities across the research pipeline from target identification to clinical trial outcomes.
- Recursion Pharmaceuticals and Exscientia have completed a landmark $700 million merger, marking the largest AI-focused life sciences deal to date and combining complementary capabilities in biological and chemical AI platforms. - The merged entity now boasts 10 programs in development and significant partnerships with pharmaceutical giants Sanofi and Roche, with their most advanced program targeting cerebral cavernous malformation in Phase 2. - Industry experts predict this merger will catalyze more AI-focused acquisitions in pharma, as companies seek to fully integrate artificial intelligence into traditional drug development processes.
